What drove SER's explosive EPS growth in Q3 2023?

Serina Therapeutics (SER) experienced a significant increase in its EPS growth rate in Q3 2023, with a year-over-year growth of 4.83% reported. This growth can be attributed to several key factors:

|code|Ticker|Name|Date|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|
|SER|SER.A|Serina Therapeutics|2023 Q1|385.7142857142857|170|
|SER|SER.A|Serina Therapeutics|2023 Q2|257.1428571428571|170|
|SER|SER.A|Serina Therapeutics|2023 Q3|483.33333333333337|170|

1. **Merger with AgeX Therapeutics**: The merger agreement between Serina Therapeutics and AgeX Therapeutics, announced on August 30, 2023, is a significant catalyst for SER's growth. The merger is expected to enhance Serina's pipeline of small molecule drug candidates targeting CNS indications, enabled by its proprietary POZ Platform™ delivery technology. This strategic move positions Serina to advance its pipeline and expand platform partnering opportunities, which could lead to increased revenue and profitability.
2. **Strategic Funding for SER-252**: Serina Therapeutics secured $5 million in strategic funding to support the advancement of its lead clinical candidate, SER-252, for advanced Parkinson's disease. This funding will enable Serina to initiate Phase 1 clinical trials for SER-252 in Q4 2025, which could lead to potential regulatory approvals and market opportunities. The issuance of convertible preferred shares at a premium price reflects investor confidence in SER-252's potential.

In conclusion, Serina Therapeutics' EPS growth in Q3 2023 can be attributed to the merger with AgeX Therapeutics, which enhances its pipeline and platform technology, and strategic funding for its lead clinical candidate, SER-252, which supports ongoing clinical development and future revenue potential.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|SER|SER.A|Serina Therapeutics|2023 Q1|385.7142857142857|0.2|170|
|SER|SER.A|Serina Therapeutics|2023 Q2|257.1428571428571|0.11|170|
|SER|SER.A|Serina Therapeutics|2023 Q3|483.33333333333337|0.23|170|